Research Reference Library · Educational Use Only

AOD-9604 for Weight Loss Research: Mechanism, Data & Protocols

Last reviewed 2026 · Source: peer-reviewed preclinical literature

What is AOD-9604?

AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment of human growth hormone (hGH) consisting of amino acids 176–191 of the hGH C-terminal region. Unlike full hGH, AOD-9604 does not activate the IGF-1 axis and has no significant effect on blood glucose or insulin sensitivity — its mechanism is selectively lipolytic.

Mechanism: Lipolysis Without IGF-1 Activation

AOD-9604 binds to the beta-3 adrenergic receptor (ADRB3) in adipose tissue, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage). This receptor selectivity is the key distinction from full hGH: full hGH stimulates lipolysis through hGHR-mediated IGF-1 production and has systemic anabolic effects; AOD-9604 achieves the lipolytic effect directly at the adipocyte without the anabolic downstream signaling.

Preclinical Research Data

Animal studies (rodent and primate models) demonstrated that AOD-9604 reduced body weight by up to 50% over 19 days compared to controls when administered at 500 mcg/kg daily. In vitro studies confirmed dose-dependent stimulation of lipolysis in isolated adipocytes. Clinical Phase 2 trials in obese adults (METAOD001-3) showed modest but statistically significant fat mass reduction over 12 weeks at doses of 1 mg and 2 mg daily.

Research Dosing Protocols

ProtocolDoseFrequencyDuration
Low-dose250 mcgDaily SC4–8 weeks
Standard500 mcgDaily SC8–12 weeks
High-dose1000 mcgDaily SC12 weeks max

AOD-9604 is typically administered in the morning on an empty stomach, as insulin inhibits lipolysis and may blunt the peptide's fat-mobilising effect when co-administered with meals.

Combination Research

AOD-9604 has been studied in combination with GLP-1 agonists (Semaglutide, Tirzepatide) in research contexts, as the mechanisms are complementary: GLP-1 agonists reduce caloric intake through appetite suppression while AOD-9604 directly mobilises stored fat for oxidation. QSC supplies both AOD-9604 (injectable, 5 mg vials) and GLP-1 compounds for research.

Research-grade peptides with HPLC-verified COA
All compounds referenced in this guide are available at QSC Peptides (qscpeptide.com) — US domestic warehouse, fast shipping, batch-level certificates of analysis.

This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.